Compliance Rate
Compliance Rate
0%
Compliant submissions
0
Incompliant submissions
0
Total trials
0
My Organizations' Clinical Trials
Showing 2 of 2 entries
View as:
Phase: N/A
Priority: Normal
Start: 12/13/17
End: 03/23/23
Due: 03/23/24
Phase: N/A
Priority: Normal
Start: 01/01/14
End: 07/30/15
Due: 07/30/16
| Title | NCT ID | Organization | User | Status | Start Date | End Date | Reporting Due Date | Last Checked | User Role | Org Created |
|---|---|---|---|---|---|---|---|---|---|---|
| Safety and Immunogenicity of Repeated Doses of ABvac40 in Patients With a-MCI or Vm-AD | NCT03461276 | Araclon Biotech S.L. | user2@example.com | None | 2017-12-13 | 2023-03-23 | 2024-03-23 | - | - | 2025-07-14 |
| Repeated Subcutaneous Administration of ABvac40 in Mild to Moderate Alzheimer's Disease Patients | NCT03113812 | Araclon Biotech S.L. | user2@example.com | None | 2014-01-01 | 2015-07-30 | 2016-07-30 | - | - | 2025-07-14 |